Pharmacodynamics of EV-077 in healthy volunteers


This peer-reviewed article in the Journal of Thrombosis illustrates the pharmacodynamic effects of EV-077, one of our legacy pharma products. Licensed to Norwegian group Serodus ASA, EV-077 is being developed for diabetic nephropathy, a progressive kidney disease caused by diabetes

Journal of Thrombosis & Thrombolysis

  • Topped our upper estimate! Evolva raises CHF 86M ($86M). Cash position now > CHF 100M ($100M).

Sign up to receive our
Press Releases!

Sign up